Beijing Luzhu Biotechnology Co., Ltd.

北京绿竹生物技术股份有限公司

02480.HK

Develops recombinant human vaccines and therapeutic biologics for infectious diseases, cancer, and autoimmune diseases, with three clinical-stage and four pre-clinical product candidates, primarily in China with target markets including the U.S. and other jurisdictions.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Backlog and project economics
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Adverse change after the track record
• Related-party transactions and balances
• Chapter 18A biotech
• Other